Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-24-078587
Filing Date
2024-07-09
Accepted
2024-07-09 17:05:56
Documents
13
Period of Report
2024-05-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A tm2419108d2_8ka.htm   iXBRL 8-K/A 25918
  Complete submission text file 0001104659-24-078587.txt   203632

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA avbp-20240516.xsd EX-101.SCH 3015
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20240516_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20240516_pre.xml EX-101.PRE 22359
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2419108d2_8ka_htm.xml XML 4350
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41929 | Film No.: 241108038
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)